ASCO GU 2021

Prostate Cancer

Lu177 as a promising new therapy for metastatic prostate cancer

Presented By

Dr Michael Hofman, Peter MacCallum Cancer Centre, Australia

Trial

Phase 2, TheraP

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 14:49

Role of prostate cancer genomics is evolving

Presented By

Dr Ashley Ross, Feinberg School of Medicine, Northwestern University, Chicago, USA

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 14:49

Apalutamide prolongs progression-free survival in prostate cancer

Presented By

Dr Dana Rathkopf, Memorial Sloan Kettering Cancer Center, New York, USA

Trial

Phase 3, ACIS

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 14:49

Dose-intensified radiation therapy fails to provide better outcomes in prostate cancer

Presented By

Prof. Pirus Ghadjar, Charité Universitätsmedizin Berlin, Germany

Trial

Phase 3, SAKK 09/10

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 14:48

Intrinsic tumour biology may be predictive of treatment response in prostate cancer

Presented By

Prof. Felix Feng, University of California San Francisco, USA

Trial

Phase 3, SPARTAN

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 14:46

Final TITAN trial results favour use of apalutamide

Presented By

Dr Kim Chi, British Columbia Cancer and Vancouver Prostate Centre, Canada

Trial

Phase 3, TITAN

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 14:46

Penile Cancer

Renal Cancer

Superior clinical outcomes and QoL with nivolumab plus cabozantinib in RCC

Presented By

Prof. David Cella, Robert H. Lurie Comprehensive Cancer Centre, Northwestern University, Illinois, USA

Trial

Phase 3, CheckMate 9ER

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 14:53

Lenvatinib plus pembrolizumab prolongs survival in renal cell carcinoma

Presented By

Dr Robert Motzer, Memorial Sloan Kettering Cancer Centre, New York, USA

Trial

Phase 3, CLEAR

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 14:53

Inflammatory markers may guide treatment decisions in metastatic renal cell cancer

Presented By

Ms Vishwani Chauhan, University of Edinburgh, UK

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 14:53

Clinical trial exclusion criteria may lead to lack of evidence in real-world patients: how do the excluded fare?

Presented By

Dr Diana Maslov, Ochsner Health System, Louisiana, USA

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 14:53

Axitinib offers hope for improving renal cell cancer surgical outcomes

Presented By

Prof. Grant Stewart, University of Cambridge, UK

Trial

Phase 2, NAXIVA

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 14:53

Cabozantinib as possible new first-line therapy in translocation renal cell carcinoma

Presented By

Dr Jonathan Thouvenin, Institut de Cancerologie Strasbourg Europe, France

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 14:52

Predictors of oral anti-cancer agent utilisation in renal cell carcinoma

Presented By

Prof. Stephanie Wheeler, University of North Carolina, USA

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 14:52

Denosumab plus pembrolizumab in advanced clear cell renal cell carcinoma

Presented By

Dr Craig Gedye, Calvary Mater Newcastle, Australia

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 14:52

Testicular Cancer

New prediction model for brain metastasis in germ cell tumours

Presented By

Dr Ryan Ashkar, Indiana University Simon Comprehensive Cancer Centre, USA

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 14:58

Reduction in radiation exposure is possible in testicular seminoma surveillance

Presented By

Prof. Robert Huddart, Royal Marsden Hospital and Institute of Cancer Research, UK

Trial

Phase 3, TRISST

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 14:58

New therapeutic option for early metastatic seminoma

Principal Investigator

Prof. Siamak Daneshmand, University of Southern California, USA

Trial

Phase 2, SEMS

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 14:57

Urothelial Cancer

Poorer outcomes in bladder cancer predicted by race/ethnicity and gender

Presented By

Dr Shaakir Hasan, New York Proton Centre, USA

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 15:03

Enfortumab vedotin as a promising treatment option for bladder cancer: phase 3 results

Presented By

Dr Thomas Powles, Barts Cancer Centre, UK

Trial

Phase 3, EV-301

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 15:03

Enfortumab vedotin as a promising treatment option for bladder cancer: phase 2 results

Presented By

Dr Arjun Vasant Balar, NYU Langone Medical Oncology, USA

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 15:02

New standard of care recommended for patients with upper tract urothelial cancer

Presented By

Dr Alison Birtle, Rosemere Cancer Centre, UK

Trial

Phase 3, POUT

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 15:02

Signature DNA alterations in subtypes of bladder cancer

Presented By

Dr Andrew Thomas Lenis, Memorial Sloan Kettering Cancer Centre, New York, USA

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 15:02

ACE inhibitors associated with superior responses in bladder cancer

Presented By

Dr Jonathan Thomas, Beth Israel Deaconess Medical Centre, Massachusetts, USA

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 15:02

Better allocation of research dollars needed

Presented By

Ms Jeenan Kaiser, University of Alberta, Canada

Conference

ASCO GU 2021

24 March 2021 15:02

Better prediction of favourable responses to immune checkpoint inhibitors in mUC

Presented By

Dr Marie Alt, Princess Margaret Cancer Centre, Canada

Conference

ASCO GU 2021

24 March 2021 15:02

Genitourinary Oncology